West Pharmaceutical director granted 791 shares
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 791 | $0.00 | $0.00 |
Footnotes (1)
- F1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.
Key Figures
Key Terms
restricted stock units financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did West Pharmaceutical (WST) director Molly Joseph receive in this insider filing?
Is the Molly Joseph transaction in West Pharmaceutical (WST) an open-market stock purchase?
When will Molly Joseph’s restricted stock units in West Pharmaceutical (WST) vest?
What does the A code mean in the West Pharmaceutical (WST) insider transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.